RussianPatents.com

Method of treating chronic viral hepatitis c. RU patent 2459629.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely hepatology and may be applicable in treating chronic viral hepatitis C. That is ensured by introducing short-lived interferon-alpha (IFN) and the nucleoside analogue Ribamidil in the patient with an initial average week dosage specified in the range of 10.5 to 21.0 mil. IU depending on the level of native patient's interferon-alpha. Interferon-alpha is introduced with at least twice gradually increase of the average week dose to 21.0 to 84 mil. IU. Over the whole period of introducing IFN, the patient is prescribed with additional antiviral preparations - an interferon inducer, as well as an amantadin preparation or a glycyrrhizic acid preparation. It is combined with a support therapy involving the introduction of T-cell immunity stimulators and preparations for correction of side effects. The presence of blood viral ribonucleic acid is occasionally controlled and the introduction of Ribamidil is started in a daily dose of 800-1200 mg from the third month from the beginning of treatment if observing the presence of ribonucleic acid or from the tenth month if observing the absence. The treatment is continued until at least a 12-month aviremia period is achieved.

EFFECT: using the presented method allows reducing aggression of antiviral therapy combined with increase of a stable positive therapeutic effect.

4 ex, 2 tbl, 2 dwg

IPC classes for russian patent Method of treating chronic viral hepatitis c. RU patent 2459629. (RU 2459629):

A61P31/14 - for RNA viruses

A61P1/16 - for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

A61K38/21 - Interferons

A61K31/4196 -

Another patents in same IPC classes:

Cattle viral diarrhoeia vaccine / 2457859
Invention refers to veterinary virology and biotechnology, and concerns a cattle viral diarrhoeia vaccine (CVDV). The described vaccine contains an avirulent and purified antigen material of the strain NADL-FGBI "Federal Centre for Animal Health" of the CVDV virus deposited in the collection of Federal State Institution Russian National Centre for Quality and Standartisation of Drugs and Feed for Animals (FGU VGNKI), No. NADL-FGBI "Federal Centre for Animal Health DEP prepared in the passaged mammal cell culture (the passaged cell cultures Taurus-2, PS and RBT) of infectious activity not less than 6,0 lg TCD50/cm3 and ELISA activity not less than 6.6 log2 to inactivation, in the effective amount, and target additives aluminium hydroxide (AHO) and saponin.

Method for producing macrocyclic compounds / 2456296
Present patent claim discloses sulphonyl-substituted compounds of formula QUIN which are used for the purpose of a method for producing a macrocyclic compound of formula (I)

2-(2,5-dimethyl)pyrazolyl-3-hydroxy-4(3h)-chinazolinon possessing antiviral, antibacterial and fungicide activity and its production method / 2451683
Invention relates to a new medication possessing antiviral, antibacterial and fungicide activity and representing 2-(2,5-dimethyl)pyrazolyl-3-hydroxy-4(3H)-chinazolinon with formula I Additionally, the invention relates to a method: for production of compounds with formula I. The method consists in subjecting 3-hydroxy-4(3H)-chinazolinon to interaction with hydrazine resulting in formation of 2-hydrazino-3-hydroxy-4(3H)-chinazolinon that is then subjected to interaction with acetyl acetone to produce the target product.

Hcv/hiv inhibitors and their application / 2448976
In claim described are organic compounds of formula I where radicals are given in description, which are applicable for elimination, prevention or alleviation of one or more symptoms, associated with HCV disorders.

Oral care compositions containing combinations of antibacterial agents and agents changing carrier body reaction / 2448711
Present invention covers compositions for local oral applications containing a combination of an antibacterial agent and an anti-inflammatory agent in an orally acceptable carrier. Specifically, what is offered is the composition for local oral application in the form of a mouthwash for treating and preventing dental deposit or gingivitis, containing in an orally acceptable carrier, in a combination: (a) riboflavin, and (b) cetylpyridinium chloride (CPC).

Composition for treating hepatitis c and method of treating hepatitis c / 2447899
Group of inventions refers to medicine and concerns a composition for treating hepatitis C and a method of treating hepatitis C. Substance of the inventions involves the composition for treating hepatitis C consisting of dendritic cells produced of patient's monocytes with NS3 protein fragments and activated patient's T-lymphocytes with the NS3 protein fragments containing the sequence 1027-1218. The method of treating involves injection of the prepared composition into the patient.

Influenza vaccine and method for preparing it / 2446824
Invention refers to medicine and concerns an influenza vaccine and method for preparing it. Substance of the invention involves the influenza vaccine containing the coupling of purified influenza virus antigens and a polymeric carrier representing 2-methyl-5-vinylpyridine and N-vinylpyrrolidone copolymer in proportions 1: 5-30, and a method for preparing the influenza vaccine involving the cultivation of influenza virus strain in chicken embryos to produce a purified viral concentrate that is followed by inactivating, splitting the viral concentrate to produce the purified influenza virus antigens and coupling with the polymer carrier representing 2-methyl-5-vinylpyridine and N-vinylpyrrolidone copolymer in proportions 1: 5-30.

Recombinant bluetongue vaccine / 2446823
Group of inventions refers to medicine and concerns a recombinant bluetongue vaccine. Substance of the invention involves versions of an immunogenic composition for inducing an immune response on Orbivirus, more specifically a bluetongue virus (BTV) in an animal susceptible to BTV infection The composition may contain a pharmaceutically or veterinary acceptable binding agent or an excipient and a vector. The vector may contain a heterologous model (s) of nucleic acid expressing in vivo BTV antigen, immunogen or their VP2 and VP5 protein epitope in an animal's body. The composition may contain an adjuvant such as carbomer. Besides, the invention involves a method for inducing an immunological or protective response, and a kit.

Methods and intermediate products / 2446171
Invention refers to methods for producing protease inhibitors, particularly serine protease inhibitors.

Pyrido [2,3-d] pyrimidines, useful as hcv inhibitors and synthesis methods thereof / 2444522
Invention relates to novel pyrido[2,3-d]pyrimidines of formula (V) and use of compounds of formula (I), containing a compound of formula (V), to prepare a medicinal agent used for inhibiting HCV replication in mammals infected with HCV, as well as a pharmaceutical composition based on said compounds. In formula (I)

Method of prevention and treatment of liver disease with application of receptor a<sub>2b</sub> antagonists

Method of prevention and treatment of liver disease with application of receptor a_2b antagonists / 2457842
Group of inventions relates to field of medicine. Method of treatment and prevention of liver fibrosis includes peroral introduction to mammal of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione. Method of reducing hepatotoxic side effects of chemical therapy or radiotherapy includes peroral introduction to mammal who underwent such treatment of therapeutically efficient amount of antagonist of adenosine receptor A2B - 3-ethyl-1-propyl-8-(1-{[3-(trifluormethyl)phenyl]methyl}pyrazol-4-yl) -1,3,7-trihydropurine-2,6-dione.

Granule and method for making thereof / 2456980
Invention refers to pharmaceutics. A pharmaceutical granule is spherical or spheroidal and has volume density 0.6-1.3 g/ml and disintegration 0.5-5 minutes. Active pharmaceutical ingredients are preparations of Traditional Chinese Medicine, herbal preparations or their extracts with a nucleus made of an extract of Traditional Chinese Medicine or herbal preparations, and a pharmaceutically acceptable carrier. The content of the pharmaceutically acceptable carrier with respect to total granule weight makes 10-60 wt %. The granule diameter can be equal to 700-1500 mcm. The granule nucleus diameter can be equal to 200-750 mcm. The granule can be also coated with a layer of 2-5 wt % with respect of total granule weight. A method for making the granules consists in introducing initial granules into a layer of a fluidised material as an excipient; the active pharmaceutical ingredients are prepared in the form of a suspension or a solution of the viscosity controlled within 6.0-9.8 MPa·s with using a viscosity-control agent; then they are sprayed over a surface of the initial granule for making a finished granule.

Method for preventing and treating hepatic consequences of ischemia / 2456678
Liver is resected in an animal experimentally. A pharmacological protection is presented by Mexicor and Serotonine Adipinate. On the operation day, 5% Mexicor is used in the form of intravenous slow stream introductions twice - 35 minutes before the operation in a dose of 5 mg/kg of weight and 11 hours after the first introduction in a dose of 7 mg/kg of weight. Serotonine Adipinate dissolved in 5 ml of isotonic solution NaCl is used in the form of intravenous slow stream introductions three times - 1 hour before the operation in a dose of 0.15 mg/kg of weight, 2 hours after the first introduction in a dose of 0.2 mg/kg of weight, 10 hours after the first introduction in a dose of 0.1 mg/kg of weight. During the postoperative period, Mexicor and Serotonine Adipinate are introduced for 8 days. Mexicor is introduced three times a day at 9 o'clock in a dose of 2.5 mg/kg of weight, at 15 o'clock in a dose of 1.5 mg/kg of weight, at 21 o'clock in a dose of 6 mg/kg of weight. Serotonine Adipinate is introduced twice a day - at 8 o'clock in a dose of 0.15 mg/kg of weight, at 17 o'clock in a dose of 0.1 mg/kg of weight.

Benzimidazole derivatives, based pharmaceutical composition and methods of using them / 2456276
Present invention refers to new benzimidazole derivatives of general formula (I) or to its pharmacologically acceptable salts wherein R1 represents a C6-aryl group which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), or a heterocyclic group which represents pyridyl, dihydrobenzofuranyl, 1,3-benzodioxolyl, tetrahydropyranyl, tetrahydrofuranyl which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), R2 represents a C1-C6 alkyl group, R3 represents a C6-aryl group which can be substituted by 1-2 groups optionally specified in a group of substitutes (a), Q represents a group represented by formula =CH-, or a nitrogen atom and a group of substitutes (a) represents a group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a carboxyl group, a C2-C7 alkylcarbonyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, an amino group, a 4-morpholinyl group and a di-C1-C6 alkyl)amino group. Also, the invention refers to a pharmaceutical composition based on a compound of formula (I), to a PPARγ activator/modulator based on the compound of formula (I), to using the compound of formula (I), to a method of reducing blood glucose, to a method of activating PPARγ, a method of treating and/or preventing said pathological conditions.

Method of preventing liver injury in formation of syndrome of combined dystrophic-degenerative changes of mesenchimal derivatives in case of local chronic inflammatory process and means for its realisation / 2455988
Claimed is means for prevention (prophylaxis) of liver injury in formation of syndrome of combined dystrophic-degenerative changes of mesenchimal derivatives in case of local chronic inflammatory process, located outside the liver (CDDCMD in case of LCIP located outside the liver), which represents hormone of pineal gland - melatonin and corresponding method of prevention (prophylaxis) of liver injury in formation of CDDCMD in case of LCIP.

Method of treating dyskinesia of gallbladder at background of chronic psycho-emotional stress / 2455970
Invention relates to medicine, namely to physiotherapy, gastroenterology. Method includes introduction of diet No5, internal intake of mineral water with the following carrying out transverse galvanisation of epigastrium area, general coniferous baths and impact with physical factor. As physical factor used is electromagnetic radiation of extremely high frequency (EHF). Impact is performed by broad-band noise emitter with frequency 40-63 GHz. Impact is performed on 3 and 4 projection zones in area of the right hypochondrium and on the area of sternum. Impact is performed daily, 10 minutes on each zone. Course includes 10-12 procedures.

Method for stimulating liver regeneration in fibrotic changes in experiment / 2455701
Under the conditions of modelling cirrhosis in experiment, the preparation EMBRYOBLASTE is introduced in liver tissue by means of an injector needle at the depth up to 0.1 cm. The preparation is introduced along a front surface of the liver, 2 injections in each lobe of the liver to form a papula. The volume of one injection makes 0.3 ml.

Use of xanthohumol and isoxanthohumol as active substance for preventing and/or controlling liver diseases / 2454996
Group of inventions refers to medicine and aims at preventing and treating a liver diseases. What is used is xanthohumol of formula (I) or xanthohumol metabolite as an active substance for making a preparation for preventing and/or controlling the liver diseases caused by obesity and/or diabetes. The daily dose varies within 0.01 to 161 mg/kg of weight. The xanthohumol content in the composition makes 0.1 to 99 wt %.

New piperazine amide derivatives / 2454412
Invention refers to new piperazine amide derivatives of formula wherein X represents N or CH; Y represents N or CH; R1 represents lower alkyl, phenyl, phenyl-lower alkyl wherein phenyl can be optionally substituted by 1-2 substitutes independently specified in a group consisting of halogen, lower alkyl; R2 represents lower alkyl, phenyl, naphthyl or heteroaryl specified in dimethylisoxazolyl, quinolinyl, thiophenyl or pyridinyl wherein phenyl or heteroaryl are optionally substituted by 1 substitute optionally specified in a group consisting of halogen, lower alkoxy group, fluor-lower alkyl, lower alkoxy-carbonyl and phenyl; R3 represents phenyl, pyridinyl or pyrazinyl wherein phenyl, pyridinyl or pyrazinyl are substituted by 1-2 substituted optionally specified in a group consisting of halogen, lower alkyl and fluor-lower alkyl; R4, R5, R6, R7, R8, R9, R10 and R11 independently represent hydrogen, as well as to their physiologically acceptable salts. These compounds are bound with LXR alpha and LXR beta, and are applicable as therapeutic agents for treatment and/or prevention of high lipid levels, high cholesterol levels, low HDL cholesterol, high LDL cholesterol, atherosclerotic diseases, diabetes, non insulin dependent diabetes mellitus, metabolic syndrome, dislipidemia, sepsis, inflammatory diseases, infectious diseases, skin diseases, colitis, pancreatitis, cholestasis, liver fibrosis, psoriasis, Alzheimer's disease, etc.

Hepatoprotector / 2454243
Invention refers to medicine and pharmacology, and concerns a hepatoprotector prepared of Amur maackia. The hepatoprotector representing Amur maackia extract which contains up to 70% of 7-O-[β-D-glucopyranosyl-(1→6)]-β-D-glucopyranoside genistein, pseudobaptigenine, formononetin, 5-methoxydaidzein and maackianine.

Antiviral and antimicrobial composition / 2457857
Invention refers to pharmaceutical industry. A composition represents a powder containing a substance comprising recombinant human interferon-α and target additives able to form a stable foam structure, specified in: polyethylene glycol, albumin, gelatine, pectin, casein, caseinate, casein hydrolysate, hydroxypropyl cellulose, polyglucin, dextrin, tragacanth, aerosil, mannitol or their mixtures; it is characterised by porous structure and fragility, has a relative disintegration shrinkage at least 10 %, equivalent pore diameter 10-110 mcm at particle size no more than 100 mcm and a resting angle less than 50° and represented in the form of a solid capsule in the following proportions in 1.0 g of the composition: human recombinant interferon-α - 10000-3000000 IU; target additives - the rest with the capsule coated with a layer of a enterosoluble substance specified in: shellac, oleic acid, hydroxypropyl cellulose, cellulose acetate phthalate, bee wax, Tween-20, Tween-80, castor oil, polyethylene oxide or their mixture. The maximum isotropic filling of the preset volume of the solid capsules ensures precise dosages of recombinant human interferon-α.